Trevi Therapeutics Charts Cash-Rich Path Through Key Trials

Trevi Therapeutics ((TRVI)) has held its Q1 earnings call. Read on for the main highlights of the call.

Trevi Therapeutics’ latest earnings call balanced confidence with realism as management laid out a cash-rich, multi-year plan anchored by Haduvio in IPF-related chronic cough. Executives highlighted regulatory momentum, a bolstered balance sheet and imminent trial starts, while openly acknowledging competitive P2X3 readouts, trial sizing risks and regulatory dependencies as key execution variables.

Strong Cash Position and Extended Runway

Trevi ended Q1 2026 with about $172M in cash, equivalents and securities, then added roughly $162M from an April stock offering, bringing pro forma cash to around $334M. Management argued this financing removes a major overhang, providing runway into 2030 and funding several value-defining studies without near-term capital pressure.

Regulatory Alignment and Phase III IPF Trial Starts

The company reported a constructive FDA meeting for its IPF-related chronic cough program, with Phase III protocols finalized and global sites identified. Trevi expects to start the first of two pivotal IPF Phase III studies this quarter and the second in H2 2026, aiming to build a registration-quality package around Haduvio.

Adaptive Strategy in Non-IPF Interstitial Lung Disease

Beyond IPF, Trevi is designing an adaptive Phase II/III program in non-IPF interstitial lung disease–related cough, though timing hinges on FDA concurrence. The company plans to submit an adaptive protocol and, if the agency agrees, initiate the trial in H2 2026, potentially accelerating the path to a broader ILD label.

RCC Phase IIb Design and Sample-Size Reestimation

Trevi will also launch a Phase IIb trial in refractory chronic cough this quarter, using three doses of Haduvio plus placebo in a parallel-arm design. The study includes a blinded sample-size reestimation at 50% enrollment, targeting about 80% conditional power with a futility band near 30–40%, and expects an SSRE readout in Q4 2026.

Advancing Intellectual Property Through 2039 and Beyond

The company has secured a core method-of-treatment patent for IPF-related chronic cough in Europe, adding to an existing U.S. patent and giving protection through 2039. Trevi has also filed additional U.S. applications that, if granted, could extend protection to 2046 and is pursuing label-enablement patents to protect dosing and other use details.

Building Operational Scale and Clinical Expertise

Trevi is quietly scaling its organization, adding roughly 10 employees since its Phase IIb results, including hires with clinical and pulmonology depth. Management pointed to strong investigator interest, active CRO collaborations and ongoing site qualification as proof that the company can run multiple programs in parallel.

Scientific and Commercial Visibility Initiatives

The team is boosting its scientific profile with six accepted submissions at the upcoming ATS conference, spanning presentations and posters. An Investor & Analyst Day will further detail clinical data and early commercial insights, including dyspnea analyses and CORAL sub-analyses that could resonate with payers.

Clinical Signal Strength and Favorable Placebo Benchmark

Trevi emphasized that the CORAL trial showed a placebo response under 20% in IPF chronic cough, which is a supportive benchmark for future studies. Management believes Haduvio can exceed the placebo-adjusted benefit seen with P2X3 agents, thanks to its combined central and peripheral mechanism, potentially differentiating it in a crowded field.

Competitive Overhang from P2X3 Pipeline Readouts

Executives flagged upcoming P2X3 outcomes, including camlipixant data, as a key source of uncertainty for the chronic cough market. Positive competitor results could validate the category but intensify competition, while weaker readouts might shift payers’ and physicians’ expectations and reshape Trevi’s go-to-market strategy.

Potential Trial Upsizing and Cost Inflation

The embedded SSRE features in RCC and planned ILD studies mean trials could be upsized if interim conditional power falls short of targets. While this improves the odds of statistical success, it also introduces potential increases in patient numbers, timelines and spend, echoing precedents seen in other respiratory and cough programs.

Placebo Variability and RCC Enrollment Risks

Trevi acknowledged that refractory chronic cough populations show more volatile placebo responses than IPF, complicating power assumptions. To mitigate this, the RCC trial will use design tools like run-in periods, but management conceded that residual placebo variability could still affect outcomes and sample-size decisions.

Regulatory Dependencies and Patent Duration Constraints

The non-IPF-ILD program’s timing remains contingent on FDA agreement with the adaptive plan, leaving open the possibility of delay or redesign. Additionally, while core patents run to 2039, extending exclusivity to 2046 depends on successful prosecution of new filings, creating some uncertainty around long-term IP protection.

No Current Revenue and Future Launch Funding Needs

Trevi reiterated that it has no commercial revenue and that its cash runway covers development and pre-commercial work, not a full product launch. If Haduvio gains approval, especially in IPF-related chronic cough, the company may need additional capital or partnerships to finance commercialization and market build-out.

Guidance and Forward Pipeline Milestones

Looking ahead, management guided that current cash plus April proceeds should fund operations into 2030, including potential FDA approval for IPF-related chronic cough and key RCC and non-IPF-ILD studies. Investors should watch for initiation of the first IPF Phase III this quarter, RCC Phase IIb kickoff with an SSRE update in Q4 2026 and a possible H2 2026 start for adaptive ILD trials pending FDA feedback.

Trevi’s call painted a picture of a well-funded specialty player leaning into a pivotal development window for Haduvio. With regulatory momentum, diversified cough indications and expanding IP protection, the upside hinges on clean trial execution and how the competitive P2X3 landscape evolves over the next few years.